Prognostic impact of tumour-infiltrating lymphocytes and cancer-associated fibroblasts in patients with pancreatic adenocarcinoma of the body and tail undergoing resection

被引:10
作者
Delayre, T. [1 ]
Guilbaud, T. [1 ]
Resseguier, N. [1 ]
Mamessier, E. [1 ]
Rubis, M. [1 ]
Moutardier, V [1 ]
Fara, R. [1 ]
Berdah, S., V [1 ]
Garcia, S. [1 ]
Birnbaum, D. J. [1 ]
机构
[1] Aix Marseille Univ, Hop Nord, AP HP, Fac Med Marseille,Digest & Oncol Surg Unit, Chemin Bourrely, F-13915 Marseille 20, France
关键词
T-CELLS; STROMA; MICROENVIRONMENT; SURVIVAL; DISTINCT; MARGIN;
D O I
10.1002/bjs.11434
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background The prognosis of patients with pancreatic cancer remains poor and novel therapeutic targets are required urgently. Treatment resistance could be due to the tumour microenvironment, a desmoplastic stroma consisting of cancer-associated fibroblasts and tumour-infiltrating lymphocytes (TILs). The aim of the study was to evaluate the prognostic value of TILs and cancer-associated fibroblasts (CAFs) in pancreatic cancer of the body and tail. Methods Using tissue microarray from resected left-sided pancreatic cancer specimens, the immunohistochemistry of TILs (cluster of differentiation (CD) 45, CD3, CD4, FoxP3 and CD8), CAFs (vimentin and alpha-smooth muscle actin (alpha SMA)) and functional markers (PD-L1 and Ki-67) was examined, and the association with disease-free (DFS) and overall (OS) survival investigated using a computer-assisted quantitative analysis. Patients were classified into two groups, with low or high levels or ratios, using the 75th percentile value as the cut-off. Results Forty-three patients were included in the study. Their median DFS and OS were 9 and 27 months respectively. A high CD4/CD3 lymphocyte ratio was associated with poorer DFS (8 months versus 11 months for a low ratio) (hazard ratio (HR) 2 center dot 23, 95 per cent c.i. 1 center dot 04 to 4 center dot 61; P = 0 center dot 041) and OS (13 versus 27 months respectively) (HR 2 center dot 62, 1 center dot 11 to 5 center dot 88; P = 0 center dot 028). A low alpha SMA/vimentin ratio together with a high CD4/CD3 ratio was correlated with poorer outcomes. No significant association was found between Ki-67, PD-L1 and survival. Conclusion In patients with resected left-sided pancreatic cancer, a tumour microenvironment characterized by a high CD4/CD3 lymphocyte ratio along with a low alpha SMA/vimentin ratio is correlated with poorer survival.
引用
收藏
页码:720 / +
页数:14
相关论文
共 42 条
[1]  
American Joint Committee on Cancer, 2017, AJCC CANC STAGING MA
[2]   Prognostic value of PDL1 expression in pancreatic cancer [J].
Birnbaum, David J. ;
Finetti, Pascal ;
Lopresti, Alexia ;
Gilabert, Marine ;
Poizat, Flora ;
Turrini, Olivier ;
Raoul, Jean-Luc ;
Delpero, Jean-Robert ;
Moutardier, Vincent ;
Birnbaum, Daniel ;
Mamessier, Emilie ;
Bertucci, Francois .
ONCOTARGET, 2016, 7 (44) :71198-71210
[3]   Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors [J].
Birnbaum, David Jeremie ;
Bertucci, Francois ;
Finetti, Pascal ;
Birnbaum, Daniel ;
Mamessier, Emilie .
CANCERS, 2019, 11 (04)
[4]   Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas [J].
Brennan, MF ;
Kattan, MW ;
Klimstra, D ;
Conlon, K .
ANNALS OF SURGERY, 2004, 240 (02) :293-298
[5]   Stromal biology of pancreatic cancer [J].
Chu, Gerald C. ;
Kimmelman, Alec C. ;
Hezel, Aram F. ;
DePinho, Ronald A. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 101 (04) :887-907
[6]  
Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO
[7]  
2-5
[8]   FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].
Conroy, T. ;
Hammel, P. ;
Hebbar, M. ;
Ben Abdelghani, M. ;
Wei, A. C. ;
Raoul, J. -L. ;
Chone, L. ;
Francois, E. ;
Artru, P. ;
Biagi, J. J. ;
Lecomte, T. ;
Assenat, E. ;
Faroux, R. ;
Ychou, M. ;
Volet, J. ;
Sauvanet, A. ;
Breysacher, G. ;
Di Fiore, F. ;
Cripps, C. ;
Kavan, P. ;
Texereau, P. ;
Bouhier-Leporrier, K. ;
Khemissa-Akouz, F. ;
Legoux, J. -L. ;
Juzyna, B. ;
Gourgou, S. ;
O'Callaghan, C. J. ;
Jouffroy-Zeller, C. ;
Rat, P. ;
Malka, D. ;
Castan, F. ;
Bachet, J. -B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406
[9]   Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer [J].
Costa, Ana ;
Kieffer, Yann ;
Scholer-Dahirel, Alix ;
Pelon, Floriane ;
Bourachot, Brigitte ;
Cardon, Melissa ;
Sirven, Philemon ;
Magagna, Ilaria ;
Fuhrmann, Laetitia ;
Bernard, Charles ;
Bonneau, Claire ;
Kondratova, Maria ;
Kuperstein, Inna ;
Zinovyev, Andrei ;
Givel, Anne-Marie ;
Parrini, Maria-Carla ;
Soumelis, Vassili ;
Vincent-Salomon, Anne ;
Mechta-Grigoriou, Fatima .
CANCER CELL, 2018, 33 (03) :463-+
[10]   Defining the molecular pathology of pancreatic body and tail adenocarcinoma [J].
Dreyer, S. B. ;
Jamieson, N. B. ;
Upstill-Goddard, R. ;
Bailey, P. J. ;
McKay, C. J. ;
Biankin, A. V. ;
Chang, D. K. .
BRITISH JOURNAL OF SURGERY, 2018, 105 (02) :E183-E191